Haemophilia-Haemostasis Unit, St. Sophia Children's Hospital, Athens, Greece.
Van Creveldkliniek, University Medical Centre Utrecht, Utrecht, The Netherlands.
Haemophilia. 2018 Mar;24(2):283-290. doi: 10.1111/hae.13387. Epub 2017 Dec 15.
Inhibitor development in previously untreated patients (PUPs) with severe haemophilia A is a multifactorial event. It is unknown whether paediatric vaccinations given in close proximity to factor VIII (FVIII) are associated with inhibitor development.
To assess whether paediatric vaccinations in close proximity to FVIII within the first 75 exposure days (EDs) are associated with inhibitor development in PUPs with severe haemophilia A.
We included 375 PUPs with severe haemophilia A (<0.01 IU/mL) from the PedNet Registry who had received vaccinations between the first and 75th ED or inhibitor development. Inhibitor risk was compared between patients who did and who did not receive vaccinations within 24, 72 or 120 hours of FVIII infusion. Unadjusted and adjusted hazard ratios were calculated for any or repeated vaccinations in close proximity to FVIII, using Cox regression.
Inhibitor development occurred in 77 of 375 patients (20.5%). Overall inhibitor development appeared similar or lower in patients receiving vaccinations in close proximity to FVIII as compared to patients receiving vaccinations without FVIII: for 24 hours, this was 19.2% and 21.4% (P = .186), for 72 hours, 16.4% and 27.3% (P = .023) and for 120 hours, 18.3% and 25.0% (P = .085), respectively.
We found no association between vaccinations given in close proximity to FVIII exposure within the first 75 EDs and inhibitor development. Our data do not support avoiding administration of FVIII at time of routine vaccinations.
在未曾接受过治疗的重度血友病 A 患者(PUP)中,抑制剂的产生是一个多因素事件。目前尚不清楚在给予 FVIII 治疗期间或前后不久接种儿科疫苗是否会增加抑制剂的产生。
评估在接受 FVIII 治疗的前 75 个暴露日(ED)内密切接触 FVIII 时接种儿科疫苗是否与 PUP 中重度血友病 A 的抑制剂发展相关。
我们纳入了来自 PedNet 注册中心的 375 名接受 FVIII 治疗期间或前后不久接种疫苗且 FVIII 活性<0.01 IU/mL 的 PUP 患者。比较了在 FVIII 输注后 24、72 或 120 小时内接种疫苗与未接种疫苗的患者中抑制剂风险。采用 Cox 回归分析计算任何或重复接种疫苗与 FVIII 密切接触的未调整和调整后的风险比。
375 名患者中有 77 名(20.5%)发生了抑制剂发展。总体而言,与未接种 FVIII 疫苗的患者相比,在 FVIII 治疗期间或前后不久接种疫苗的患者发生抑制剂发展的情况似乎相似或更低:24 小时时,前者为 19.2%,后者为 21.4%(P=0.186);72 小时时,前者为 16.4%,后者为 27.3%(P=0.023);120 小时时,前者为 18.3%,后者为 25.0%(P=0.085)。
我们没有发现 FVIII 暴露的前 75 个 ED 内密切接触 FVIII 治疗时接种疫苗与抑制剂发展之间存在关联。我们的数据不支持在常规接种疫苗时避免给予 FVIII 治疗。